Mechanism of Action

diABZI STING agonist-1 trihydrochloride is a dimeric amidobenzimidazole (diABZI) compound that directly binds and activates STING, a key innate immune adaptor protein located on the endoplasmic reticulum membrane. Unlike cyclic dinucleotide (CDN) STING agonists, diABZI is a non-nucleotide small molecule with enhanced cell permeability, enabling efficient intracellular target engagement.

Upon binding STING, the compound induces STING dimerization and conformational changes that trigger downstream signaling through TBK1 (TANK-binding kinase 1) and IRF3 (interferon regulatory factor 3), culminating in robust production of type I interferons (IFN-α/β) and pro-inflammatory cytokines. Activation of NF-κB signaling may also occur, amplifying the inflammatory response.

This mechanism makes diABZI STING agonist-1 trihydrochloride a valuable pharmacological tool for studying innate immune signaling and for evaluating STING as a therapeutic target in oncology and infectious disease models.

Reconstitution and Storage Guidelines

Solubility: diABZI STING agonist-1 trihydrochloride is soluble in water and DMSO. The trihydrochloride salt form confers improved aqueous solubility compared to the free base, facilitating preparation of stock solutions for cell-based and in vivo studies.

Recommended reconstitution: Prepare stock solutions by dissolving the compound in sterile water or DMSO at an appropriate concentration (e.g., 10–50 mM in DMSO or aqueous buffer). Vortex briefly and allow to equilibrate at room temperature. Filter-sterilize aqueous solutions using a 0.22 µm membrane if intended for cell culture or in vivo dosing.

Storage: Store lyophilized powder at –20 °C, protected from light and moisture. Once reconstituted, aliquot stock solutions and store at –80 °C to minimize freeze-thaw degradation. Avoid repeated freeze-thaw cycles. Reconstituted solutions should be used within the timeframe validated for your specific application.

Note: Specific solubility values, recommended working concentrations, and stability data should be confirmed against the lot-specific Certificate of Analysis (CoA) provided with each shipment.

Experimental Applications and Protocols

Cell-based assays: diABZI STING agonist-1 trihydrochloride is widely used to stimulate STING signaling in human and murine cell lines, including monocyte-derived cells, macrophages, dendritic cells, and tumor cell lines. Typical working concentrations range from low nanomolar to low micromolar depending on cell type and assay readout; researchers should perform dose-response optimization for each experimental system.

Readouts: Common endpoints include quantification of IFN-β, IFN-α, and downstream cytokines (e.g., IL-6, TNF-α) by ELISA or multiplex assay; assessment of IRF3 and TBK1 phosphorylation by western blot; and evaluation of STING-dependent gene expression by RT-qPCR or RNA-seq.

In vivo studies: diABZI has been employed in mouse models to evaluate anti-tumor immunity and systemic innate immune activation. Route of administration, dosing schedule, and vehicle selection should be optimized based on the specific model. Systemic cytokine responses should be monitored as part of safety assessment.

Controls: Always include vehicle control (matched solvent at equivalent volume/concentration) and, where appropriate, a STING-knockout or STING-inhibitor control to confirm target specificity.

Safety and Handling Precautions

diABZI STING agonist-1 trihydrochloride is a potent immunostimulatory compound intended for research use only. Appropriate laboratory safety precautions must be observed at all times.

• Personal protective equipment (PPE): Wear appropriate gloves, lab coat, and eye protection when handling the compound in powder or solution form.
• Exposure avoidance: Avoid inhalation of dust or aerosols and prevent skin or mucous membrane contact. Given its potent STING-activating activity, minimize unnecessary human exposure.
• Waste disposal: Dispose of compound-containing waste in accordance with your institution's chemical waste management procedures and applicable local regulations.
• Not for human or veterinary use: This compound is strictly for in vitro and preclinical research applications and must not be administered to humans or used as a pharmaceutical or veterinary product.

Consult the Safety Data Sheet (SDS) associated with product D655125 for complete hazard information before use.